8-K: Impact BioMedical Secures Loan Amendment with DSS, Inc., Extending Maturity to 2030

Impact BioMedical, Inc. has amended its revolving promissory note with DSS, Inc., extending the maturity date to September 30, 2030, and increasing the principal balance to $12,859,328.60.

Summary

• Impact BioMedical, Inc. and DSS, Inc. have agreed to amend their existing revolving promissory note.
• The amendment extends the loan's maturity date to September 30, 2030.
• The principal balance of the loan has increased to $12,859,328.60, which includes previously advanced principal and accrued interest.
• The amendment eliminates any further advance options under the original note.
• Specific repayment terms have been established, including monthly interest payments until January 2026, followed by fixed monthly payments of $126,380.80 until August 2030, and a final payment in September 2030.
• The interest rate is now a floating rate of WSJ Prime + 0.50%, initially set at 9%, with a post-maturity rate capped at 18% or the maximum allowed by law.
• Impact BioMedical can prepay the loan without penalty.
• The loan is secured by a blanket first lien on all of Impact BioMedical's assets, including licenses and patents.
• DSS, Inc. is the majority shareholder of Impact BioMedical.

Sentiment

Score: 6

Explanation: The document indicates a necessary restructuring of debt, which is neither overly positive nor negative. The extended maturity provides stability, but the high post-maturity interest rate and blanket lien are concerning.

Positives

• The extension of the maturity date to 2030 provides Impact BioMedical with long-term financial stability.
• The ability to prepay the loan without penalty offers flexibility.
• The establishment of a structured repayment plan provides clarity on future obligations.

Negatives

• The loan is secured by a blanket first lien on all of Impact BioMedical's assets, which could be a risk if the company defaults.
• The floating interest rate exposes Impact BioMedical to potential increases in borrowing costs.
• The post-maturity interest rate of up to 18% is very high.

Risks

• The floating interest rate could increase the cost of borrowing if the WSJ Prime Rate rises.
• Defaulting on the loan could result in the loss of all assets due to the blanket first lien.
• The high post-maturity interest rate could significantly increase the amount owed if the loan is not repaid by the maturity date.
• The company is reliant on DSS, Inc. for funding, which could be a risk if DSS's financial situation changes.

Future Outlook

The amendment provides Impact BioMedical with a structured repayment plan and extended maturity, aiming to provide long-term financial stability.

Industry Context

This type of loan amendment is common for companies seeking to restructure their debt and extend repayment terms, especially when dealing with a major shareholder as a lender.

Comparison to Industry Standards

• The interest rate of WSJ Prime + 0.50% is within the typical range for secured loans of this nature, although the specific rate will depend on the borrower's creditworthiness and the prevailing market conditions.
• The repayment terms, including monthly interest payments followed by fixed principal and interest payments, are a standard approach to amortizing debt.
• The blanket first lien on all assets is a common security measure for lenders, particularly when dealing with smaller or riskier borrowers.
• Comparable companies in the biotech sector often use similar financing structures, including convertible notes and secured loans, to fund their operations and research.

Related Party Transactions

• DSS, Inc., the lender, is the majority shareholder of Impact BioMedical, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the extended maturity as a positive sign of financial stability, but the increased debt and security could be a concern.
• Employees may be indirectly affected by the company's financial health and ability to operate.
• Creditors may be impacted by the first lien on all assets, which could affect their recovery in case of default.

Next Steps

• Impact BioMedical will begin making monthly interest payments on February 1, 2024.
• Impact BioMedical will make monthly principal and interest payments of $126,380.80 from February 1, 2026, to August 31, 2030.
• Impact BioMedical will make a final payment of all outstanding principal and interest on September 30, 2030.

Key Dates

Keywords

promissory note, loan, debt, financing, maturity date, interest rate, repayment, DSS Inc, Impact BioMedical, lien